Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy

Matthew Matasar, MD, chief, Division of Blood Disorders, hematologist, oncologist, professor of medicine, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, discusses the primary analysis of the phase 1 ELM-1 study (NCT02290951) assessing the efficacy and safety of odronextamab (Ordspono) monotherapy in patients with diffuse large B-cell lymphoma following treatment with CAR T-cell therapy. Matasar and colleagues shared this data during the 2024 ASH Annual Meeting.